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Abstract
Background: Melanoma is the major cause of skin cancer death worldwide. Parkinson’s disease is a neurodegenerative disorder
that is caused by mutation of a-synuclein or other genes. Importantly, epidemiological studies have reported co-occurrence of
melanoma and Parkinson’s disease, suggesting that these two diseases could share common genetic components.
Methodology/Principal Findings: Recently, we found that human melanoma cell lines highly express a-synuclein, whereas
the protein is undetectable in the non-melanoma cancer cell lines tested. To investigate the expression of a-synuclein in
human melanoma tissues, we immunostained sections of melanoma, nevus, non-melanocytic cutaneous carcinoma, and
normal skin. a-Synuclein was positively detected in 86% of the primary and 85% of the metastatic melanoma sections, as well
as in 89% of nevus sections. However, a-synuclein was undetectable in non-melanocytic cutaneous carcinoma and normal skin.
Conclusions/Significance: The Parkinson’s disease-related protein, a-synuclein, is expressed in both malignant and benign
melanocytic lesions, such as melanomas and nevi. Although a-synuclein cannot be used to distinguish between malignant
and benign melanocytic skin lesions, it might be a useful biomarker for the diagnosis of metastatic melanoma.
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Introduction
Malignant melanoma is the major cause of skin cancer
mortality, and its incidence is rising worldwide [1,2]. Clinical
and histological variables such as primary tumor invasion,
ulceration, and lymph node status might fail to identify early
stage disease that will eventually progress [3]. Therefore, an
accurate histological diagnosis is only the first step towards a
rational and effective treatment for melanoma [2]. Histological
biomarkers might help us to diagnose and identify patients with
early-stage melanoma who are likely to develop advanced disease
and would benefit from additional therapies [3]. S-100, HMB-45,
and MART-1 are well known biomarkers for melanoma, and
antibodies against these molecules have been used for immuno-
staining to diagnose malignant melanoma [4].
Specifically, the anti-S-100 antibody demonstrates excellent
sensitivity because the S-100 protein is expressed in almost all primary
and metastatic malignant melanomas. Unfortunately, however, S-100
has limited specificity; it is expressed in many other malignant tumors
[4]. HMB-45 and MART-1 are melanocyte-specific proteins and are
most commonly used as melanocytic markers. Although HMB-45 is
highly specific to melanoma, the clinical utility of HMB-45 is limited
because it is not expressed by 20% to 40% of metastatic melanomas
[4,5,6]. MART-1 has been reported to be more specific and more
sensitive than HMB-45 in both primary and metastatic melanoma
[4,7,8]. MART-1 has also been demonstrated to have a higher
diagnostic accuracy than S-100 and HMB-45 staining [4,9]. Thus,
MART-1 currently seems to be the most useful histological biomarker
for the diagnosis of melanoma.
Recently, epidemiological studies have suggested a link between
melanoma and Parkinson’s disease (PD), a neurodegenerative
disease associated with mutations of a-synuclein [10,11,12]. a-
Synuclein is a highly charged 140-amino-acid protein that is
predominantly expressed in central nervous system neurons,
where it is localized around synaptic vesicles in presynaptic
terminals [13]. Although the function of a-synuclein is still unclear,
genetic studies have demonstrated that point mutation or
amplification of the a-synuclein gene can cause neurodegenerative
disorders, termed a-synucleinopathies, such as PD and dementia
with Lewy bodies (DLB) [13]. Thus, a-synuclein is involved in the
pathogenesis of neurodegenerative disorders, but its relationship
with melanoma remains unknown.
In this study, we demonstrate that a-synuclein is highly
expressed in melanoma cell lines, both primary and metastatic
melanoma tissues, and nevus tissues.
Materials and Methods
Cell Lines and Culture Conditions
We purchased the following human cell lines from American
Type Culture Collection (Manassas, VA): SH-SY5Y, SK-MEL28,
K562, HEK293, HeLa, HT1080, HL60, SW620, U937, U2OS,
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U251MG were generous gifts from Dr. Fred Wang (Harvard
Medical School) and Dr. Yoshiki Saito (M. D. Anderson Cancer
Center), respectively. K562, HL60, U937, Y79, and BJAB cells
were maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum and antibiotics. Other cell lines were maintained in
Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum and antibiotics.
Antibodies
Mouse monoclonal anti-a-synuclein antibodies 4D6 and 7B12.2
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA)
and Chemicon (Temecula, CA), respectively. Mouse monoclonal
anti-HMB-45 antibody was purchased from Santa Cruz Biotech-
nology. Rabbit monoclonal anti-MART-1 antibody was pur-
chased from Epitomics (Burlingame, CA). Rabbit polyclonal anti-
actin antibody was purchased from Sigma (St. Louis, MO).
Western Blot Analysis
Protein samples were treated for 1 h at 50uC in 2% SDS
treating solution. After SDS-PAGE, Western blot analysis was
performed according to the protocol provided with the ECL
detection system (Amersham Pharmacia Biotech). Horseradish
peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG anti-
body (Santa Cruz Biotechnology) was used as a secondary
antibody.
Immunohistochemistry
To immunostain human tissues of malignant melanoma, nevus,
non-melanocytic cutaneous carcinoma (squamous cell carcinoma
and basal cell carcinoma), and normal skin, tissue microarray
slides were purchased from Imgenex (San Diego, CA) and US
Biomax (Rockville, MD). Slides were incubated in an oven at 60uC
for 30 min, deparaffinized, and pretreated with Target Retrieval
solution (Dako, Carpinteria, CA). Slides were next incubated with
anti-a-synuclein antibody 4D6 at dilution 1:100 for 1 h at room
temperature, followed by washing with PBS. Slides were then
incubated with alkaline phosphatase-conjugated anti-mouse IgG
(Jackson ImmunoResearch Laboratories, West Grove, PA) for 1 h
at room temperature and rinsed with PBS. Bound antibody was
detected with Liquid Permanent Red substrate (Dako). Slides were
then counterstained with hematoxylin (Richard-Allan Scientific,
Kalamazoo, MI) and mounted. The slides were examined with an
Axio Imager M1 microscope (Zeiss).
Double Immunostaining for a-Synuclein and MART-1
A tissue microarray slide (Imgenex) was incubated in an oven at
60uC for 30 min. The slide was then deparaffinized and pretreated
with Target Retrieval solution (Dako). Next, the slide was
incubated with mouse monoclonal anti-a-synuclein (4D6) anti-
body at a dilution 1:100 and rabbit monoclonal anti-MART-1
(EP1422Y) antibody at a dilution of 1:20,000 for 1 h at room
temperature. After washing, the slide was labeled with Cy2-
conjugated AffiniPure F(ab’)2 fragment donkey anti-mouse IgG for
a-synuclein and Cy3-conjugated AffiniPure F(ab’)2 fragment
donkey anti-rabbit IgG for MART-1 at a dilution of 1:500 for
1 h at room temperature. These secondary antibodies were
purchased from Jackson ImmunoResearch Laboratories. Finally,
the slide was analyzed by an Axio Imager M1 microscope (Zeiss).
The localization of a-synuclein was shown by the green
fluorescence of Cy2. The localization of MART-1 was shown by
the red fluorescence of Cy3. Their colocalization was examined by
the merging of both fluorescent images.
Results
a-Synuclein and Melanoma Markers are Specifically
Expressed in SK-MEL28 Cells
Although a-synuclein is predominantly expressed in central
nervous system neurons [13], which human cell lines highly express
a-synuclein is not known. We therefore performed Western blotting
to examine the expression levels of a-synuclein in 11 human cell
lines: SH-SY5Y (neuroblastoma), SK-MEL28 (malignant melano-
ma), K562 (erythroleukemia), HEK293 (human embryonic kidney
cell), HeLa (cervical adenocarcinoma), HT1080 (lung fibrosarco-
ma), HL60 (promyelocytic leukemia), BJAB (Burkitt’s lymphoma),
SW620 (colon adenocarcinoma), U937 (myeloid leukemia), and
U2OS (osteosarcoma). As a positive control, we used HeLa cell
transfectants expressing FLAG-tagged a-synuclein. As shown in
Fig. 1, a-synuclein, as well as the melanoma markers MART-1 and
HMB-45, was strongly expressed in the malignant melanoma SK-
MEL28 cell line, but was undetectable in the other cell lines,
suggesting that a-synuclein is specifically expressed in malignant
melanoma SK-MEL28 cells.
a-Synuclein Is Undetectable in Cell Lines of Brain Tumors
and Retinoblastoma
Since a-synuclein is predominantly expressed in the nervous
system [13], we used Western blotting to examine its expression
Figure 1. Expression levels of a-synuclein in human non-
melanoma cell lines. Expression of endogenous a-synuclein was
examined in different non-melanoma cancer cell lines by Western
blotting using two different mouse monoclonal anti-a-synuclein
antibodies (4D6 and 7B12.2). A total cell lysate of HeLa cells expressing
FLAG-tagged a-synuclein was loaded as a positive control. To
demonstrate expression of melanoma markers, we performed Western
blotting using monoclonal antibodies against MART-1 and HMB-45. To
demonstrate equal loading amounts of total cell lysates, Western
blotting using anti-actin antibody was also performed (bottom panel).
The detected proteins are indicated on the right. Molecular size markers
are shown in kilodaltons.
doi:10.1371/journal.pone.0010481.g001
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including the retinoblastoma Y79 cell line and 4 brain tumor cell
lines, SH-SY5Y (neuroblastoma), SK-NSH (neuroblastoma),
U251MG (glioblastoma), and Daoy (medulloblastoma). HeLa cell
transfectants expressing FLAG-tagged a-synuclein and SK-
MEL28 cells were used as positive controls. As shown in Fig. 2,
the expression of a-synuclein was undetectable in the brain tumor
and retinoblastoma cell lines tested.
a-Synuclein Is Expressed in Some Melanoma Cell Lines
a-Synuclein protein is highly expressed in the human malignant
melanoma SK-MEL28 cell line, suggesting that it may be
expressed in other melanoma cell lines. To test this possibility,
we examined the expression levels of a-synuclein and two
melanoma markers (MART-1 and HMB-45) in 3 other malignant
melanoma cell lines, A-375, MeWo, and WM266-4, by Western
blotting. HeLa cell transfectants expressing FLAG-tagged a-
synuclein and SK-MEL28 cells were used as positive controls.
As shown in Fig. 3, a-synuclein was strongly detected in MeWo
and SK-MEL28 cells and weakly detected in WM266-4 cells,
whereas it was undetectable in A-375 cells. Interestingly, both
MeWo and SK-MEL28 were also positive for the melanosome-
related marker proteins MART-1 and HMB-45, but A-375 was
negative for them. WM266-4 was weakly positive for MART-1
and negative for HMB-45. These results suggest that a-synuclein is
involved in melanosomes or melanogenesis.
a-Synuclein Is Expressed in Malignant Melanoma Tissues
To examine the expression of a-synuclein in human malignant
melanoma tissue samples, we immunostained 132 melanoma
sections with antibody to a-synuclein. These tissue sections were
derived from 98 primary lesions and 34 metastatic lesions.
Surprisingly, 86% of the primary melanoma samples and 85%
of the metastatic melanoma samples were positive for a-synuclein
(Table 1).
Fig. 4 shows 9 of 132 samples of melanoma immunostainings.
Panel A shows anti-a-synuclein immunostaining of primary
melanoma (skin, face) from a 70-year-old female. a-Synuclein-
positive, atypical melanoma cells are scattered in the dermis as well
as infiltrating into the epidermis. The degree of pigmentation
varies. Lymphocytic infiltration is present. Panel B shows
Figure 2. Expression levels of a-synuclein in cell lines of human
brain tumors and retinoblastoma. Expression of endogenous a-
synuclein was examined in cell lines of human brain tumors and
retinoblastoma by Western blotting using mouse monoclonal anti-a-
synuclein antibody 4D6. Total cell lysates of HeLa cells expressing FLAG-
tagged a-synuclein and SK-MEL28 cells were loaded as positive
controls. To demonstrate expression of melanoma markers, we
performed Western blotting using monoclonal antibodies against
MART-1 and HMB-45. To demonstrate equal loading amounts of total
cell lysates, Western blotting using anti-actin antibody was also
performed (bottom panel). The detected proteins are indicated on
the right. Molecular size markers are shown in kilodaltons.
doi:10.1371/journal.pone.0010481.g002
Figure 3. Expression levels of a-synuclein in human melanoma
cell lines. Expression of endogenous a-synuclein was examined in
melanoma cell lines by Western blotting using mouse monoclonal anti-
a-synuclein antibody 4D6. Total cell lysates of HeLa cells expressing
FLAG-tagged a-synuclein and SK-MEL28 cells were loaded as positive
controls. To demonstrate expression of melanoma markers, we
performed Western blotting using monoclonal antibodies against
MART-1 and HMB-45. To demonstrate equal loading amounts of total
cell lysates, Western blotting using anti-actin antibody was also
performed (bottom panel). The detected proteins are indicated on
the right. Molecular size markers are shown in kilodaltons.
doi:10.1371/journal.pone.0010481.g003
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year-old female. There is nodular proliferation of melanoma cells
in the nests without pigment production but with high expression
of a-synuclein. Panel C shows immunostaining of primary
melanoma (skin, left buttock) from a 55-year-old male. a-
Synuclein-positive melanoma cells are proliferating in the dermis.
Half of the melanoma cells generate melanin pigments. Vessel-like
structures are observed. Panel D shows immunostaining of
primary uveal melanoma (eyeball) from a 53-year-old male.
Heavily pigmented melanoma cells can be seen. Some cells have
less melanin pigments but express high levels of a-synuclein. Panel
E shows immunostaining of primary melanoma (rectum) from a
38-year-old female. There is proliferation of spindle-shaped
melanoma cells with a-synuclein expression but without pigment
production. Panel F shows immunostaining of primary melanoma
(anus) from a 77-year-old male. There is proliferation of
melanoma cells with a-synuclein expression but without pigment
production. Panel G shows immunostaining of metastatic
melanoma (lymph node, right oxter) from a 44-year-old male.
The lymph node is packed with round metastatic cells that express
a-synuclein but do not produce melanin pigments. Panel H shows
immunostaining of metastatic melanoma (lymph node, left groin)
from a 72-year-old female. Metastatic melanoma cells are heavily
pigmented in the lymph node. Some cells have less melanin
pigments but express high levels of a-synuclein. Panel I shows
immunostaining of metastatic melanoma (lung) from a 59-year-old
male. Melanoma cells with a-synuclein expression but without
brown melanin pigments are packed in the alveolar spaces,
whereas melanoma cells with brown melanin pigments line on the
alveolar walls. Nucleoli are prominent in melanoma cells.
Thus, a-synuclein can be immunostained in various types of
malignant melanoma tissues.
a-Synuclein Is Expressed in MART-1-negative Melanoma
Cells
MART-1 has currently been the most useful histological
biomarker for malignant melanoma [4,9]. To determine whether
a-synuclein is more useful than MART-1 as a histological
biomarker for melanoma, we double-immunostained 56 melano-
ma sections (derived from 42 primary lesions and 14 metastatic
lesions) with both mouse monoclonal anti-a-synuclein antibody
and rabbit monoclonal anti-MART-1 antibody (see Fig. 5 and
Table 2). For primary melanoma, 86% of samples were positive
for a-synuclein and 76% of samples were positive for MART-1.
For metastatic melanoma, 86% of samples were positive for a-
synuclein and 71% of samples were positive for MART-1 (Table 2).




Primary melanoma: 98 14 (14%) 84 (86%)
Metastatic melanoma: 34 5 (15%) 29 (85%)
Total: 132 19 (14%) 113 (86%)
Lesions of primary melanoma (98 cases) include 84 skin, 4 eye, 3 anus, 2 nasal
cavity, 2 rectum, and 3 vulva. Lesions of metastatic melanoma (34 cases) include
31 lymph nodes, 2 lungs, and 1 small intestine.
doi:10.1371/journal.pone.0010481.t001
Figure 4. Expression of a-synuclein in human malignant melanoma tissues. Tissue sections of 132 melanoma samples were immunostained
with mouse monoclonal anti-a-synuclein antibody 4D6 (see text for identification of samples). The sections were then incubated with an alkaline
phosphatase-conjugated anti-mouse IgG. After washing, Liquid Permanent Red substrate was used to develop the reaction and detect a-synuclein-
positive cells. The sections were then counterstained with hematoxylin and analyzed by microscopy. The localization of a-synuclein is shown by the
red color of Liquid Permanent Red substrate. Nuclear counterstaining is shown by the blue color of hematoxylin. Melanin pigments are brown in
melanoma cells. Scale bar indicates 50 mm.
doi:10.1371/journal.pone.0010481.g004
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more cases of both primary and metastatic melanoma.
In Fig. 5A and B, we show 2 melanoma sections immunostained
with both mouse monoclonal anti-a-synuclein antibody and rabbit
monoclonal anti-MART-1 antibody. These sections were selected
from 56 immunostained sections. Specifically, Fig. 5A shows
double immunostaining of metastatic melanoma (lymph node)
from a 47-year-old male. a-Synuclein is expressed in many round-
shaped melanoma cells; both the cytoplasm and prominent
nucleoli are immunostained (panel a). MART-1 is expressed only
in the cytoplasm (panel b). Importantly, some a-synuclein-positive
cells express MART-1 (shown by yellow and orange cells in panel
c). However, other a-synuclein-positive cells do not (shown by
green cells in panel c). Fig. 5B shows double immunostaining of
primary melanoma (popliteal region) from a 56-year-old male. a-
Synuclein is expressed in many spindle-shaped melanoma cells
(panel a). MART-1 is expressed in the cytoplasm of some cells
(panel b). Importantly, some a-synuclein-positive cells express
MART-1 (shown by yellow and orange cells in panel c). However,
other a-synuclein-positive cells do not (shown by green cells in
panel c). Thus, a-synuclein is expressed in MART-1-negative
melanoma cells in many cases.
Melanoma Cells Highly Expressing a-Synuclein Generate
No or Low Levels of Melanin Pigments
To investigate the relationship between the expression of a-
synuclein and the generation of melanin pigments, we analyzed 17
tissue sections containing melanin-positive melanoma cells. Fig. 6
shows the a-synuclein immunostaining of metastatic melanoma
(inguinal lymph node) from a 57-year-old female. We first
acquired a bright field image to determine the localization of
melanin pigments (panel a). The image of brown pigments was
then inverted and the color was converted to red (panel b). As
shown in panels a and b, almost half of the cells generate melanin
pigments. Importantly, cells highly expressing a-synuclein show no
or a very low level of melanin pigments (panels c and d). This
finding was observed in all of the immunostained sections that are
strongly positive for a-synuclein.
a-Synuclein Is Expressed in Nevus Tissues
To examine the expression of a-synuclein in benign melanocytic
lesions, we immunostained 19 nevus sections with antibody to a-
Figure 5. Relationship of a-synuclein with MART-1 in human
malignant melanoma tissues. To investigate the relationship
between a-synuclein and MART-1, tissue sections of melanoma samples
(A and B) were double-immunostained with both mouse monoclonal
anti-a-synuclein (4D6) antibody and rabbit monoclonal anti-MART-1
(EP1422Y) antibody. The sections were then labeled with Cy2-
conjugated anti-mouse IgG for a-synuclein and Cy3-conjugated anti-
rabbit IgG for MART-1. Finally, the sections were analyzed by
fluorescence microscopy. The localization of a-synuclein is shown by
the green fluorescence of Cy2 (panel a). The localization of MART-1 is
shown by the red fluorescence of Cy3 (panel b). Their colocalization was
examined by the merging of both fluorescent images (panel c). Scale
bar indicates 20 mm.
doi:10.1371/journal.pone.0010481.g005
Table 2. Comparison between a-synuclein and MART-1
immunoreactivities in malignant melanoma.
a-Synuclein MART-1
Negative Positive Negative Positive
Primary melanoma: 42 6 (14%) 36 (86%) 10 (24%) 32 (76%)
Metastatic melanoma: 14 2 (14%) 12 (86%) 4 (29%) 10 (71%)
Total: 56 8 (14%) 48 (86%) 14 (25%) 42 (75%)
Lesions of primary melanoma (42 cases) include 33 skin, 3 eye, 2 anus, 2 nasal
cavity, and 2 rectum. Lesions of metastatic melanoma (14 cases) include 11
lymph nodes, 2 lungs, and 1 small intestine.
doi:10.1371/journal.pone.0010481.t002
Figure 6. Relationship of a-synuclein with melanin pigments in
human malignant melanoma tissues. To investigate the relation-
ship of a-synuclein with melanin pigments, tissue sections of
pigmented melanoma were immunostained with mouse monoclonal
anti-a-synuclein antibody 4D6. The sections were analyzed by
fluorescence microscopy to determine the localization of a-synuclein
and by bright field microscopy to determine the localization of melanin
pigments. The localization of a-synuclein is shown by the green
fluorescence of Cy2 (panel c). The localization of melanin pigments is
shown by the brown color in the bright field microscopy (panel a). The
localization of melanin pigments is shown by the red color in the dark
field (panel b) because the image of brown pigments (panel a) was
inverted and the color was then converted to red (panel b). In panel d,
the image of panel b is merged with panel c. Scale bar indicates 20 mm.
doi:10.1371/journal.pone.0010481.g006
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nevus samples, 11 intradermal nevus samples, and 2 junctional
nevus samples. As summarized in Table 3, 83% of the compound
nevus samples, 91% of the intradermal nevus samples, and all
samples of junctional nevus were positive for a-synuclein.
Fig. 7 shows a-synuclein immunostainings of 6 nevus samples,
which are selected from the 19 immunostainings.
Panels A–C shows immunostaining of compound nevus. The
section in panel A was derived from the right waist of a 23-year-
old female. The section in panel B was derived from the left leg of
a 25-year-old male. The section in panel C was derived from the
upper arm of a 50-year-old male. In these samples, nevus cells are
seen in the epidermis, and some have migrated into the dermis. In
panel A, a-synuclein-positive nevus cells are mainly present as
clusters at the junction between the dermis and epidermis. It
should be noted that a-synuclein is immunostained in the stratum
corneum, suggesting that a-synuclein is still stable in dead cells. In
panel B, nevus cells strongly positive for a-synuclein occur at the
junction between the dermis and epidermis, as seen in panel A.
Some nevus cells in the dermis are also positive for a-synuclein. In
panel C, some nevus cells are a-synuclein-positive in the dermis.
Panels D–F shows immunostaining of intradermal nevus. The
section in panel D was derived from the face of a 42-year-old male.
The section in panel E was derived from the rectum of a 38-year-
old female. The section in panel F was derived from the anus of a
77-year-old male. These intradermal nevi show that nevus cells are
entirely confined to nests in the dermis. Interestingly, nevus cells
that are close to the epidermis are positive for a-synuclein, whereas
nevus cells that are far from the epidermis are negative for a-
synuclein.
Thus, a-synuclein is expressed in some non-malignant melano-
cytic nevus cells.
a-Synuclein Is Undetectable in Non-melanocytic
Cutaneous Carcinoma and Normal Skin
To examine the expression of a-synuclein in tissues of non-
melanocytic cutaneous carcinoma, we performed a-synuclein
immunostaining on tissue sections derived from 6 patients with
squamous cell carcinoma and from 5 patients with basal cell
carcinoma. For each patient, 3 sections were immunostained (total
18 sections of squamous cell carcinoma and 15 sections of basal
cell carcinoma) (Table 4). Melanoma and normal skin sections
were also immunostained on the same slide as positive and
negative controls, respectively.
Fig. 8A and 8B show a-synuclein immunostainings of squamous
cell carcinoma samples. The sections in panels A and B were
derived from the chest skin of a 46-year-old male and a 73-year-
old male, respectively. a-Synuclein was undetectable in these
sections as well as the 16 other squamous cell carcinoma samples
tested.
Fig. 8C and 8D show a-synuclein immunostainings of basal cell
carcinoma samples. The section in panel C was derived from the
Table 3. Summary of a-synuclein immunoreactivity in nevi.
a-Synuclein
Negative Positive
Compound nevus: 6 1 (17%) 5 (83%)
Intradermal nevus: 11 1 (9%) 10 (91%)
Junctional nevus: 2 0 (0%) 2 (100%)
Total: 19 2 (11%) 17 (89%)
doi:10.1371/journal.pone.0010481.t003
Figure 7. Expression of a-synuclein in human nevus tissues. Using mouse monoclonal anti-a-synuclein antibody 4D6, we immunostained
tissue sections of 19 nevus samples (6 compound, 11 intradermal, and 2 junctional nevus samples) (see text for identification of samples). The
sections were then incubated with an alkaline phosphatase-conjugated anti-mouse IgG. After washing, Liquid Permanent Red substrate was used to
develop the reaction and detect a-synuclein-positive cells. The sections were then counterstained with hematoxylin and analyzed by microscopy. Six
immunostainings are selected and shown in this figure. Panels A–C, compound nevus; Panels D–F, intradermal nevus. The localization of a-synuclein
is shown by the red color of Liquid Permanent Red substrate. Nuclear counterstaining is shown by the blue color of hematoxylin. Melanin pigments
are brown. Scale bar indicates 50 mm.
doi:10.1371/journal.pone.0010481.g007
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derived from the skin of a 48-year-old male. a-Synuclein was
undetectable in these sections as well as the 13 other basal cell
carcinoma samples tested.
Fig. 8E and 8F show a-synuclein immunostainings of melanoma
samples. The section in panel E was derived from the right thigh of
a 66-year-old male. The section in panel F was derived from the
left buttock of a 75-year-old female. a-Synuclein was strongly
immunostained in both sections.
Fig. 8G and 8H show a-synuclein immunostainings of normal
skin samples. The section in panel G was derived from the
abdominal skin of a 40-year-old male. The section in panel H was
derived from the breast skin of a 49-year-old female. Although
brown melanin pigment was detected in the epidermis of both
sections, a-synuclein was undetectable.
Discussion
a-Synuclein is predominantly expressed in the brain. Point
mutation or amplification of the a-synuclein gene causes PD, in
which melanin-positive, dopaminergic neurons of the substantia
nigra are degenerated [13]. Thus, a-synuclein is involved in the
pathogenesis of PD, but its relationship with melanoma has been
unknown.
Recent epidemiological studies have reported co-occurrence of
PD and melanoma. Specifically, in a large-scale study including
over 8,000 PD cases, a diagnosis of melanoma was associated with
an approximately 50% increased risk of subsequently developing
PD [10], whereas individuals with PD had a twofold increase in
risk of subsequently developing melanoma [11]. Most recently, in
another large-scale study including approximately 160,000 people
who did not have PD, it was found that people with a family
history of melanoma were nearly twice as likely to develop PD as
people with no family history [12]. These epidemiological studies
suggest that melanoma and PD could share common genetic
components [12]. In this study, we demonstrated that both cell
lines and tissues of malignant melanoma express a-synuclein. It is
etiologically of interest that the PD-related protein, a-synuclein, is
expressed in melanoma whose co-occurrence with PD has
epidemiologically been reported.
MART-1 and HMB-45 are melanosome-related proteins
[14,15]. In this study, we demonstrated that melanoma cell lines
positive for MART-1 and HMB-45 also express a-synuclein,
suggesting that a-synuclein may be related to melanosomes or
melanogenesis. Indeed, a-synuclein was previously shown to
negatively regulate the activity of tyrosine hydroxylase [16,17],
the rate-limiting enzyme in the production of dopamine and
melanin [18,19]. In our immunohistochemical studies, melanoma
cells highly expressing a-synuclein generate no or only very low
levels of melanin pigments. In these cells, a-synuclein may inhibit
the activity of tyrosine hydroxylase [16,17] and affect melanin
production as described previously [18,19].
As discussed in the Introduction, S-100, HMB-45, and MART-
1 are commonly used as histological biomarkers for malignant
melanoma [4]. Because MART-1 staining has a higher diagnostic
accuracy than S-100 and HMB-45 staining [4,9], MART-1 has
appeared to be the most useful histological biomarker for the
diagnosis of melanoma. However, our histological studies using
double immunostaining showed that a-synuclein expresses in
MART-1-negative melanoma cells in many cases and that a-




Squamous cell carcinoma: 6 6 (100%) 0 (0%)
Basal cell carcinoma: 5 5 (100%) 0 (0%)
Total: 11 11 (100%) 0 (0%)
doi:10.1371/journal.pone.0010481.t004
Figure 8. Expression of a-synuclein in tissues of patients with
non-melanocytic cutaneous carcinoma. Using mouse monoclonal
anti-a-synuclein antibody 4D6, we immunostained skin sections of
squamous cell carcinoma (6 samples) and basal cell carcinoma (5
samples), as well as malignant melanoma (positive control) and normal
skin (negative control). The sections were then incubated with an
alkaline phosphatase-conjugated anti-mouse IgG. After washing, Liquid
Permanent Red substrate was used to develop the reaction and detect
a-synuclein-positive cells. The sections were then counterstained with
hematoxylin and analyzed by microscopy. For each malignant disease
or normal skin, two immunostainings were selected and shown in this
figure. Panels A and B, squamous cell carcinoma; Panels C and D, basal
cell carcinoma; Panels E and F, malignant melanoma; Panels G and H,
normal skin. The localization of a-synuclein is shown by the red color of
Liquid Permanent Red substrate. Nuclear counterstaining is shown by
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than MART-1. Thus, a-synuclein might be a better histological
biomarker for the diagnosis of malignant melanoma. Importantly,
however, a-synuclein is expressed in both malignant and benign
melanocytic lesions, such as melanoma and nevus, respectively.
This means that a-synuclein cannot be used to distinguish between
malignant and benign melanocytic skin lesions, but it is still very
useful for the diagnosis of metastatic melanoma. Since a-synuclein
is strongly expressed in unpigmented melanoma, as described
above, this marker would allow us to easily diagnose unpigmented
metastatic melanoma.
In conclusion, the PD-related protein, a-synuclein, is expressed
in melanoma cells. Further testing of additional primary and
metastatic tumor types will be required to evaluate the utility of a-
synuclein immunostaining in the differential diagnosis of primary
and metastatic melanoma in the clinical setting.
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